Back to today’s briefing

Story perspectives

Eli Lilly Boosts 2024 Forecast Amid Diabetes Drug Challenges

1/19/2025

27 5

Summary

Eli Lilly Boosts Forecast

Eli Lilly adjusted its 2024 revenue forecast to $45 billion, citing lower prescriptions for GLP-1 diabetes drugs Mounjaro and Zepbound.
The company expects a 44% revenue growth in Q4 and 32% for the year.
A $23 billion investment aims to boost production capacity by 60% by mid-2025, targeting international markets.
Despite recent stock volatility, analysts view Eli Lilly as a strong investment opportunity.

Summary

Eli Lilly's Mixed Quarter

Eli Lilly's Chief Administrative Officer sold 900 shares, decreasing ownership by 14.11%.
The company reported Q3 earnings of $1.18 EPS, falling short of estimates by $0.34, with $11.44 billion in revenue.
Eli Lilly raised its quarterly dividend from $1.30 to $1.50 per share, effective March 10.
Analysts' ratings vary; Deutsche Bank reduced its target to $1,015, while Wolfe Research set it at $1,000.

History

Historical Context

Eli Lilly's revenue forecast shift reflects a historical pattern of market volatility in pharmaceuticals. Similar to the 2009 fallout from illegal marketing of Zyprexa, current pressures from competition and regulatory changes challenge profitability. Past missteps inform today's cautious strategies in navigating market dynamics and consumer trust.

1 of 3

Eli Lilly Boosts Forecast

Eli Lilly adjusted its 2024 revenue forecast to $45 billion, citing lower prescriptions for GLP-1 diabetes drugs Mounjaro and Zepbound.
The company expects a 44% revenue growth in Q4 and 32% for the year.
A $23 billion investment aims to boost production capacity by 60% by mid-2025, targeting international markets.
Despite recent stock volatility, analysts view Eli Lilly as a strong investment opportunity.

1 / 3